scholarly article | Q13442814 |
P50 | author | Vladimir Valuev-Elliston | Q85980387 |
Jan Balzarini | Q93167025 | ||
Anastasia L Khandazhinskaya | Q97897994 | ||
Maria P Paramonova | Q114421051 | ||
Sergey Kochetkov | Q39382787 | ||
Alexander Ivanov | Q42321534 | ||
Robert Snoeck | Q47921736 | ||
Graciela Andrei | Q47921752 | ||
Christophe Pannecouque | Q50551511 | ||
Denis A. Babkov | Q52579558 | ||
Katherine L. Seley-Radtke | Q57405174 | ||
P2093 | author name string | Mikhail S Novikov | |
Sergey A Gavryushov | |||
P2860 | cites work | Assessment of Docking Poses: Interactions-Based Accuracy Classification (IBAC) versus Crystal Structure Deviations | Q62582760 |
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors | Q27651379 | ||
Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses | Q27652334 | ||
Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase | Q27652894 | ||
Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor | Q28323582 | ||
SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2 | Q28346130 | ||
U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication | Q28368034 | ||
L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase | Q28378789 | ||
The HIV-1 reverse transcription (RT) process as target for RT inhibitors | Q28646665 | ||
Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data | Q31161564 | ||
Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains | Q34601887 | ||
Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents | Q35673318 | ||
New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections | Q35879807 | ||
1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents | Q39477060 | ||
Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses | Q39780409 | ||
Benzhydrylquinazolinediones: novel cytosolic phospholipase A2alpha inhibitors with improved physicochemical properties | Q39844929 | ||
The structure-activity relationships of 2,4(1H,3H)-pyrimidinedione derivatives as potent HIV type 1 and type 2 inhibitors | Q40042904 | ||
Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor | Q40328156 | ||
TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. | Q40425001 | ||
New methods for the synthesis of N-benzoylated uridine and thymidine derivatives; a convenient method for N-debenzoylation | Q43884027 | ||
Interactions of the HIV-1 reverse transcriptase 'AZT-resistant' mutant with substrates and AZT-TP. | Q54235667 | ||
Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography. | Q54718103 | ||
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 1150-1158 | |
P577 | publication date | 2013-01-03 | |
P1433 | published in | Bioorganic & Medicinal Chemistry | Q2904200 |
P1476 | title | N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase | |
P478 | volume | 21 |
Q40957975 | 2-(2,4-Dioxy-1,2,3,4-Tetrahydropyrimidin-1-yl)-N-(4-Phenoxyphenyl)-Acetamides as a Novel Class of Cytomegalovirus Replication Inhibitors |
Q36175168 | 5-Arylaminouracil Derivatives as Potential Dual-Action Agents |
Q46502793 | Chemometrics approach for the prediction of structure-activity relationship for membrane transporter bilitranslocase |
Q38695987 | Design, Synthesis, and the Biological Evaluation of a New Series of Acyclic 1,2,3-Triazole Nucleosides |
Q41040182 | Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands. |
Q60949593 | Novel 5'-Norcarbocyclic Pyrimidine Derivatives as Antibacterial Agents |
Q59351314 | Recent advances in the design and development of NNRTI scaffolds |
Q42707689 | Synthesis of novel 2-(substituted amino)alkylthiopyrimidin-4(3H)-ones as potential antimicrobial agents. |
Q39095730 | Synthesis of some new benzisothiazolone and benzenesulfonamide derivatives of biological interest starting from saccharin sodium |
Q59055969 | Synthesis, Single Crystal X-Ray Structure, and Antimicrobial Activity of 6-(1,3-Benzodioxol-5-ylmethyl)-5-ethyl-2-{[2-(morpholin-4-yl)ethyl]sulfanyl}pyrimidin-4(3H)-one |
Q38740588 | Synthesis, anti-varicella-zoster virus and anti-cytomegalovirus activity of quinazoline-2,4-diones containing isoxazolidine and phosphonate substructures |
Search more.